Insider Notice: Soleil Boughton and Proposed Sale of 2,572 HIMS Shares
Rhea-AI Filing Summary
Form 144 notice: The filing reports a proposed sale of 2,572 Class A shares of Hims & Hers Health, Inc. through Fidelity Brokerage Services LLC on 08/11/2025, with an aggregate market value of $132,818.08. The company has 217,641,958 shares outstanding. The 2,572 shares were acquired on 06/15/2025 through restricted stock vesting from the issuer and were recorded as compensation.
The filing also lists recent sales by Soleil Boughton over the prior three months: seven transactions between 05/12/2025 and 07/28/2025 totaling 22,207 shares for aggregate gross proceeds of $1,228,936.95. The form includes the standard insider representation regarding material nonpublic information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Form 144 reporting a small proposed insider sale of 2,572 shares (≈0.00118% of outstanding shares).
The filing documents a proposed sale of 2,572 Class A shares valued at $132,818.08 and shows total outstanding shares of 217,641,958, allowing a simple proportion calculation: 2,572 represents about 0.00118% of outstanding stock. The shares were issued via restricted stock vesting on 06/15/2025 as compensation, indicating the sale arises from recently vested equity rather than an open-market issuance by the company. On face value and given the size relative to total capitalization, this notice is informational and unlikely to materially affect market valuation.
TL;DR: Multiple recent insider dispositions are documented; total prior sales equal 22,207 shares for $1,228,936.95.
The schedule of prior sales shows seven transactions by Soleil Boughton between 05/12/2025 and 07/28/2025 totaling 22,207 shares and aggregate gross proceeds of $1,228,936.95. Combined with the new proposed sale of 2,572 shares, the record reflects ongoing insider liquidity activity. The filing includes the standard attestation that the seller is not aware of undisclosed material adverse information. From a governance perspective, the document transparently discloses acquisitions (restricted stock vesting) and subsequent sales, enabling stakeholders to observe insider selling patterns without asserting unprovided motives.